Sotirios Evangelou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sotirios Evangelou has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Ilias Ninios
Cardiology Department Interbalkan Medical Center Thessaloniki Greece
14 shared publications - Vlasis Ninios
Cardiology Department Interbalkan Medical Center Thessaloniki Greece
14 shared publications - Georgios E. Papadopoulos
Cardiology Department Interbalkan Medical Center Thessaloniki Greece
13 shared publications - Andreas Ioannides
Cardiology Department, Interbalkan Medical Center, Thessaloniki57001, Greece
7 shared publications - Andreas Ioannidis
2nd Cardiology Department, Interbalkan Medical Center, Thessaloniki, Greece, Greece
5 shared publications - Athinodoros Nikitopoulos
Cardiology Department, Interbalkan Medical Center, 57001 Thessaloniki, Greece
4 shared publications
Latest Publications
- Open Access
Combined Mitral and Tricuspid Transcatheter Edge-to-Edge Repair: Evidence, Patient Selection, and Procedural Strategy
Concomitant mitral regurgitation (MR) and tricuspid regurgitation (TR) constitute an interconnected multivalvular syndrome, but correction of MR does not consistently reverse TR. This narrative review examines TR evolution after mitral transcatheter edge-to-edge repair (M-TEER), patient selection, imaging, procedural strategies, and evidence for treatment of both valves. Combined TEER denotes bivalvular treatment, performed during the same session or in stages. Observational cohorts report TR improvement in approximately one-third of broadly selected patients after M-TEER, with substantial variation according to baseline severity, response definition, and follow-up. Persistent or new-onset TR is associated with adverse outcomes; these associations do not establish that subsequent tricuspid intervention improves survival. Comparative registries suggest potential clinical benefit from combined treatment, whereas uncontrolled series primarily establish technical feasibility in selected patients at experienced centers. Treatment timing remains uncertain because randomized comparisons of isolated, same-session, and staged strategies are unavailable. The proposed Heart Team framework integrates lesion-specific indications, anatomical suitability, anticipated TR reversibility, physiological reserve, and patient goals. It is an unvalidated discussion aid rather than a treatment recommendation. Randomized strategy trials are needed to establish incremental clinical benefit, comparative safety, and optimal timing.
Open AccessCombined Mitral and Tricuspid Transcatheter Edge-to-Edge Repair: Evidence, Patient Selection, and Procedural Strategy
Concomitant mitral regurgitation (MR) and tricuspid regurgitation (TR) constitute an interconnected multivalvular syndrome, but correction of MR does not consistently reverse TR. This narrative review examines TR evolution after mitral transcatheter edge-to-edge repair (M-TEER), patient selection, imaging, procedural strategies, and evidence for treatment of both valves. Combined TEER denotes bivalvular treatment, performed during the same session or in stages. Observational cohorts report TR improvement in approximately one-third of broadly selected patients after M-TEER, with substantial variation according to baseline severity, response definition, and follow-up. Persistent or new-onset TR is associated with adverse outcomes; these associations do not establish that subsequent tricuspid intervention improves survival. Comparative registries suggest potential clinical benefit from combined treatment, whereas uncontrolled series primarily establish technical feasibility in selected patients at experienced centers. Treatment timing remains uncertain because randomized comparisons of isolated, same-session, and staged strategies are unavailable. The proposed Heart Team framework integrates lesion-specific indications, anatomical suitability, anticipated TR reversibility, physiological reserve, and patient goals. It is an unvalidated discussion aid rather than a treatment recommendation. Randomized strategy trials are needed to establish incremental clinical benefit, comparative safety, and optimal timing.
- Open Access
- 22 August 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (9) , 957
Myval Beyond the Aortic Valve: Device–Anatomy Interaction, Procedural Strategy, and Clinical Evidence in Mitral, Tricuspid, and Pulmonary Positions
The Myval balloon-expandable transcatheter heart valve was developed for transcatheter aortic valve implantation, but its broad 20–32 mm size matrix and controlled deployment have prompted use in non-aortic landing zones. This narrative review critically synthesizes Myval-specific case reports, case series, and observational cohorts, together with relevant platform-level evidence, addressing device design, anatomical selection, imaging, procedural strategy, clinical outcomes, and evidence gaps. Reported applications include mitral valve-in-valve, valve-in-ring, and valve-in-mitral annular calcification; tricuspid valve-in-valve and valve-in-ring; and pulmonary implantation in conduits, surgical bioprostheses, and selected native or patched right ventricular outflow tracts. Outcomes appear most predictable within circular stented surgical bioprostheses, whereas non-circular rings, severe mitral annular calcification, and compliant or aneurysmal outflow tracts present greater risks of inadequate anchoring, paravalvular regurgitation, embolization, frame deformation, left ventricular outflow tract obstruction, and coronary compression. Intermediate and extra-large diameters increase the available nominal sizing options; however, no clinical evidence demonstrates that this reduces embolization, paravalvular regurgitation, residual gradients, or reintervention. The available data document procedural feasibility in anatomically selected patients but are predominantly observational, with limited independent adjudication and follow-up. These procedures are generally off-label and should remain individualized Heart Team decisions; prospective multicenter studies are required to define comparative safety, antithrombotic management, durability, and lifetime reintervention strategies.
- 22 August 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (9) , 957
Open AccessMyval Beyond the Aortic Valve: Device–Anatomy Interaction, Procedural Strategy, and Clinical Evidence in Mitral, Tricuspid, and Pulmonary Positions
The Myval balloon-expandable transcatheter heart valve was developed for transcatheter aortic valve implantation, but its broad 20–32 mm size matrix and controlled deployment have prompted use in non-aortic landing zones. This narrative review critically synthesizes Myval-specific case reports, case series, and observational cohorts, together with relevant platform-level evidence, addressing device design, anatomical selection, imaging, procedural strategy, clinical outcomes, and evidence gaps. Reported applications include mitral valve-in-valve, valve-in-ring, and valve-in-mitral annular calcification; tricuspid valve-in-valve and valve-in-ring; and pulmonary implantation in conduits, surgical bioprostheses, and selected native or patched right ventricular outflow tracts. Outcomes appear most predictable within circular stented surgical bioprostheses, whereas non-circular rings, severe mitral annular calcification, and compliant or aneurysmal outflow tracts present greater risks of inadequate anchoring, paravalvular regurgitation, embolization, frame deformation, left ventricular outflow tract obstruction, and coronary compression. Intermediate and extra-large diameters increase the available nominal sizing options; however, no clinical evidence demonstrates that this reduces embolization, paravalvular regurgitation, residual gradients, or reintervention. The available data document procedural feasibility in anatomically selected patients but are predominantly observational, with limited independent adjudication and follow-up. These procedures are generally off-label and should remain individualized Heart Team decisions; prospective multicenter studies are required to define comparative safety, antithrombotic management, durability, and lifetime reintervention strategies.
- Open Access
- 29 July 2026
- Published by MDPI AG in Preprints.org
Myval Beyond the Aortic Valve: Device–Anatomy Interaction, Procedural Strategy, and Clinical Evidence in Mitral, Tricuspid, and Pulmonary Positions
The Myval balloon-expandable transcatheter heart valve was developed for transcatheter aortic valve implantation, but its broad 20–32-mm size matrix and controlled deployment have prompted use in non-aortic landing zones. This narrative review critically synthesizes Myval-specific case reports, case series, and observational cohorts, together with relevant platform-level evidence, addressing device design, anatomical selection, imaging, procedural strategy, clinical outcomes, and evidence gaps. Reported applications include mitral valve-in-valve, valve-in-ring, and valve-in-mitral annular calcification; tricuspid valve-in-valve and valve-in-ring; and pulmonary implantation in conduits, surgical bioprostheses, and selected native or patched right ventricular outflow tracts. Outcomes appear most predictable within circular stented surgical bioprostheses, whereas non-circular rings, severe mitral annular calcification, and compliant or aneurysmal outflow tracts present greater risks of inadequate anchoring, paravalvular regurgitation, embolization, frame deformation, left ventricular outflow tract obstruction, and coronary compression. Intermediate and extra-large sizes may facilitate closer dimensional matching, but comparative advantage has not been established. The available data document procedural feasibility in anatomically selected patients but are predominantly observational, with limited independent adjudication and follow-up. These procedures are generally off-label and should remain individualized Heart Team decisions; prospective multicenter studies are required to define comparative safety, antithrombotic management, durability, and lifetime reintervention strategies.
- 29 July 2026
- Published by MDPI AG in Preprints.org
Open AccessMyval Beyond the Aortic Valve: Device–Anatomy Interaction, Procedural Strategy, and Clinical Evidence in Mitral, Tricuspid, and Pulmonary Positions
The Myval balloon-expandable transcatheter heart valve was developed for transcatheter aortic valve implantation, but its broad 20–32-mm size matrix and controlled deployment have prompted use in non-aortic landing zones. This narrative review critically synthesizes Myval-specific case reports, case series, and observational cohorts, together with relevant platform-level evidence, addressing device design, anatomical selection, imaging, procedural strategy, clinical outcomes, and evidence gaps. Reported applications include mitral valve-in-valve, valve-in-ring, and valve-in-mitral annular calcification; tricuspid valve-in-valve and valve-in-ring; and pulmonary implantation in conduits, surgical bioprostheses, and selected native or patched right ventricular outflow tracts. Outcomes appear most predictable within circular stented surgical bioprostheses, whereas non-circular rings, severe mitral annular calcification, and compliant or aneurysmal outflow tracts present greater risks of inadequate anchoring, paravalvular regurgitation, embolization, frame deformation, left ventricular outflow tract obstruction, and coronary compression. Intermediate and extra-large sizes may facilitate closer dimensional matching, but comparative advantage has not been established. The available data document procedural feasibility in anatomically selected patients but are predominantly observational, with limited independent adjudication and follow-up. These procedures are generally off-label and should remain individualized Heart Team decisions; prospective multicenter studies are required to define comparative safety, antithrombotic management, durability, and lifetime reintervention strategies.
- Open Access
- 1 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3462
Transfemoral Valve-in-Valve TAVI with MyVal for Failed Surgical Aortic Bioprostheses: Procedural Outcomes, Serial Hemodynamics, and Anatomy-Based Determinants of Residual Gradient
Background/Objectives: Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is an established treatment for failed surgical aortic bioprostheses, but dedicated data on the MyVal platform remain limited. We evaluated outcomes, hemodynamics, residual gradient, and an exploratory matched comparison with ACURATE neo2. Methods: This prospective, single-center cohort included consecutive patients with failed surgical aortic bioprostheses treated with MyVal ViV-TAVI between July 2022 and June 2025. Outcomes were reported according to VARC-3. Results: Sixty-eight patients were included (age 77 ± 7 years; 51.5% women; EuroSCORE II 7.3 ± 1.8%). Technical success was 100%, with no 30-day death, stroke, myocardial infarction, second-valve implantation, or emergency surgical conversion. Mean gradient decreased from 38.0 ± 9.5 mmHg at baseline to 6.7 ± 2.1 mmHg post-procedure and remained low at 1 year (8.1 ± 2.5 mmHg; overall p < 0.001). AVA increased from 0.80 ± 0.23 cm2 to 1.98 ± 0.19 cm2 post-procedure and was 1.86 ± 0.23 cm2 at 1 year (overall p < 0.001). Smaller true internal diameter independently predicted elevated 1-year gradient (adjusted OR per 1-mm decrease 1.33, 95% CI 1.04–1.78; p = 0.028). In the exploratory matched comparison, safety and hemodynamic outcomes did not differ significantly between MyVal and ACURATE neo2. At a median follow-up of 12.8 months, all-cause mortality and heart failure hospitalization were each 4.4%. Conclusions: In this prospective single-center cohort, MyVal ViV-TAVI was associated with high procedural success and favorable 1-year hemodynamic outcomes, with residual gradient driven mainly by small surgical valve true internal diameter.
- 1 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3462
Open AccessTransfemoral Valve-in-Valve TAVI with MyVal for Failed Surgical Aortic Bioprostheses: Procedural Outcomes, Serial Hemodynamics, and Anatomy-Based Determinants of Residual Gradient
Background/Objectives: Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is an established treatment for failed surgical aortic bioprostheses, but dedicated data on the MyVal platform remain limited. We evaluated outcomes, hemodynamics, residual gradient, and an exploratory matched comparison with ACURATE neo2. Methods: This prospective, single-center cohort included consecutive patients with failed surgical aortic bioprostheses treated with MyVal ViV-TAVI between July 2022 and June 2025. Outcomes were reported according to VARC-3. Results: Sixty-eight patients were included (age 77 ± 7 years; 51.5% women; EuroSCORE II 7.3 ± 1.8%). Technical success was 100%, with no 30-day death, stroke, myocardial infarction, second-valve implantation, or emergency surgical conversion. Mean gradient decreased from 38.0 ± 9.5 mmHg at baseline to 6.7 ± 2.1 mmHg post-procedure and remained low at 1 year (8.1 ± 2.5 mmHg; overall p < 0.001). AVA increased from 0.80 ± 0.23 cm2 to 1.98 ± 0.19 cm2 post-procedure and was 1.86 ± 0.23 cm2 at 1 year (overall p < 0.001). Smaller true internal diameter independently predicted elevated 1-year gradient (adjusted OR per 1-mm decrease 1.33, 95% CI 1.04–1.78; p = 0.028). In the exploratory matched comparison, safety and hemodynamic outcomes did not differ significantly between MyVal and ACURATE neo2. At a median follow-up of 12.8 months, all-cause mortality and heart failure hospitalization were each 4.4%. Conclusions: In this prospective single-center cohort, MyVal ViV-TAVI was associated with high procedural success and favorable 1-year hemodynamic outcomes, with residual gradient driven mainly by small surgical valve true internal diameter.
- Open Access
- 8 April 2026
- Published by MDPI AG in Preprints.org
Transfemoral Valve-in-Valve TAVI with MyVal for Failed Surgical Aortic Bioprostheses: Procedural Outcomes, Serial Hemodynamics, and Anatomy-Based Determinants of Residual Gradient
Background/Objectives: Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is an established treatment for failed surgical aortic bioprostheses, but dedicated data on the MyVal platform remain limited. We evaluated outcomes, hemodynamics, residual gradient, and an exploratory matched comparison with ACURATE neo2. Methods: This prospective, single-center cohort included consecutive patients with failed surgical aortic bioprostheses treated with MyVal ViV-TAVI between July 2022 and June 2025. Outcomes were reported according to VARC-3. Results: Sixty-eight patients were included (age 77 ± 7 years; 51.5% women; EuroSCORE II 7.3 ± 1.8%). Technical success was 100%, with no 30-day death, stroke, myocardial infarction, second-valve implantation, or emergency surgical conversion. Mean gradient decreased from 38.0 ± 9.5 mmHg at baseline to 6.7 ± 2.1 mmHg post-procedure and remained low at 1 year (8.1 ± 2.5 mmHg; overall pConclusions: MyVal ViV-TAVI showed high procedural success and durable 1-year hemodynamic performance, with residual gradient driven mainly by small surgical valve true internal diameter.
- 8 April 2026
- Published by MDPI AG in Preprints.org
Open AccessTransfemoral Valve-in-Valve TAVI with MyVal for Failed Surgical Aortic Bioprostheses: Procedural Outcomes, Serial Hemodynamics, and Anatomy-Based Determinants of Residual Gradient
Background/Objectives: Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is an established treatment for failed surgical aortic bioprostheses, but dedicated data on the MyVal platform remain limited. We evaluated outcomes, hemodynamics, residual gradient, and an exploratory matched comparison with ACURATE neo2. Methods: This prospective, single-center cohort included consecutive patients with failed surgical aortic bioprostheses treated with MyVal ViV-TAVI between July 2022 and June 2025. Outcomes were reported according to VARC-3. Results: Sixty-eight patients were included (age 77 ± 7 years; 51.5% women; EuroSCORE II 7.3 ± 1.8%). Technical success was 100%, with no 30-day death, stroke, myocardial infarction, second-valve implantation, or emergency surgical conversion. Mean gradient decreased from 38.0 ± 9.5 mmHg at baseline to 6.7 ± 2.1 mmHg post-procedure and remained low at 1 year (8.1 ± 2.5 mmHg; overall pConclusions: MyVal ViV-TAVI showed high procedural success and durable 1-year hemodynamic performance, with residual gradient driven mainly by small surgical valve true internal diameter.
- Open Access
- 16 February 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (2) , 96
Transcatheter Paravalvular Leak Closure: A Step-by-Step Guide
Paravalvular leak (PVL) remains a clinically important complication after surgical or transcatheter valve implantation, presenting predominantly with heart failure (HF) and/or high-shear hemolysis. While redo surgery can be definitive, contemporary candidates frequently carry prohibitive operative risk, positioning transcatheter PVL closure as a key therapeutic alternative. However, available outcome data are largely derived from observational series and registries with heterogeneity in PVL mechanisms, prosthesis types, imaging protocols, and endpoint definitions. Standardized frameworks—such as those proposed by the PVL Academic Research Consortium—support harmonized PVL grading and clinically meaningful composite endpoints that integrate imaging/hemodynamic results with patient-centered outcomes. Across datasets, the most consistent determinant of benefit is residual PVL severity: procedural efficacy is most commonly defined as achieving ≤ mild residual regurgitation without prosthetic leaflet interference, device embolization, or major complications. This review provides a step-by-step, phenotype-driven approach to transcatheter PVL closure, emphasizing multimodality imaging (TEE and cardiac CT, with adjunct CMR and PET when appropriate), access and support planning tailored to valve position, and morphology-matched device selection—often requiring modular multi-device strategies for elongated crescentic channels, particularly in hemolysis-predominant presentations. We also synthesize evidence on complications and bailout management, with a focus on preventable high-severity events (leaflet impingement, embolization, stroke/air, vascular injury, tamponade) and standardized pre-release safety checks. Collectively, contemporary practice supports high implant success in experienced programs, with clinical improvement tightly coupled to procedural endpoint quality and careful Heart Team selection.
- 16 February 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (2) , 96
Open AccessTranscatheter Paravalvular Leak Closure: A Step-by-Step Guide
Paravalvular leak (PVL) remains a clinically important complication after surgical or transcatheter valve implantation, presenting predominantly with heart failure (HF) and/or high-shear hemolysis. While redo surgery can be definitive, contemporary candidates frequently carry prohibitive operative risk, positioning transcatheter PVL closure as a key therapeutic alternative. However, available outcome data are largely derived from observational series and registries with heterogeneity in PVL mechanisms, prosthesis types, imaging protocols, and endpoint definitions. Standardized frameworks—such as those proposed by the PVL Academic Research Consortium—support harmonized PVL grading and clinically meaningful composite endpoints that integrate imaging/hemodynamic results with patient-centered outcomes. Across datasets, the most consistent determinant of benefit is residual PVL severity: procedural efficacy is most commonly defined as achieving ≤ mild residual regurgitation without prosthetic leaflet interference, device embolization, or major complications. This review provides a step-by-step, phenotype-driven approach to transcatheter PVL closure, emphasizing multimodality imaging (TEE and cardiac CT, with adjunct CMR and PET when appropriate), access and support planning tailored to valve position, and morphology-matched device selection—often requiring modular multi-device strategies for elongated crescentic channels, particularly in hemolysis-predominant presentations. We also synthesize evidence on complications and bailout management, with a focus on preventable high-severity events (leaflet impingement, embolization, stroke/air, vascular injury, tamponade) and standardized pre-release safety checks. Collectively, contemporary practice supports high implant success in experienced programs, with clinical improvement tightly coupled to procedural endpoint quality and careful Heart Team selection.
- Open Access
- 14 January 2026
- Published by MDPI AG in Preprints.org
Transcatheter Paravalvular Leak Closure: A Step-by-Step Guide
Paravalvular leak (PVL) remains a clinically important complication after surgical or transcatheter valve implantation, presenting predominantly with heart failure (HF) and/or high-shear hemolysis. While redo surgery can be definitive, contemporary candidates frequently carry prohibitive operative risk, positioning transcatheter PVL closure as a key therapeutic alternative. However, available outcome data are largely derived from observational series and registries with heterogeneity in PVL mechanisms, prosthesis types, imaging protocols, and endpoint definitions. Standardized frameworks—such as those proposed by the PVL Academic Research Consortium—support harmonized PVL grading and clinically meaningful composite endpoints that integrate imaging/hemodynamic results with patient-centered outcomes. Across datasets, the most consistent determinant of benefit is residual PVL severity: procedural efficacy is most commonly defined as achieving ≤mild residual regurgitation without prosthetic leaflet interference, device embolization, or major complications. This review provides a step-by-step, phenotype-driven approach to transcatheter PVL closure, emphasizing multimodality imaging (TEE and cardiac CT, with adjunct CMR and PET when appropriate), access and support planning tailored to valve position, and morphology-matched device selection—often requiring modular multi-device strategies for elongated crescentic channels, particularly in hemolysis-predominant presentations. We also synthesize evidence on complications and bailout management, with a focus on preventable high-severity events (leaflet impingement, embolization, stroke/air, vascular injury, tamponade) and standardized pre-release safety checks. Collectively, contemporary practice supports high implant success in experienced programs, with clinical improvement tightly coupled to procedural endpoint quality and careful Heart Team selection.
- 14 January 2026
- Published by MDPI AG in Preprints.org
Open AccessTranscatheter Paravalvular Leak Closure: A Step-by-Step Guide
Paravalvular leak (PVL) remains a clinically important complication after surgical or transcatheter valve implantation, presenting predominantly with heart failure (HF) and/or high-shear hemolysis. While redo surgery can be definitive, contemporary candidates frequently carry prohibitive operative risk, positioning transcatheter PVL closure as a key therapeutic alternative. However, available outcome data are largely derived from observational series and registries with heterogeneity in PVL mechanisms, prosthesis types, imaging protocols, and endpoint definitions. Standardized frameworks—such as those proposed by the PVL Academic Research Consortium—support harmonized PVL grading and clinically meaningful composite endpoints that integrate imaging/hemodynamic results with patient-centered outcomes. Across datasets, the most consistent determinant of benefit is residual PVL severity: procedural efficacy is most commonly defined as achieving ≤mild residual regurgitation without prosthetic leaflet interference, device embolization, or major complications. This review provides a step-by-step, phenotype-driven approach to transcatheter PVL closure, emphasizing multimodality imaging (TEE and cardiac CT, with adjunct CMR and PET when appropriate), access and support planning tailored to valve position, and morphology-matched device selection—often requiring modular multi-device strategies for elongated crescentic channels, particularly in hemolysis-predominant presentations. We also synthesize evidence on complications and bailout management, with a focus on preventable high-severity events (leaflet impingement, embolization, stroke/air, vascular injury, tamponade) and standardized pre-release safety checks. Collectively, contemporary practice supports high implant success in experienced programs, with clinical improvement tightly coupled to procedural endpoint quality and careful Heart Team selection.
- 19 July 2025
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 19 (4) , 387-389
Key takeaways from the 2025 expert consensus document on cardiac computed tomography for prosthetic heart valve assessment
- 19 July 2025
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 19 (4) , 387-389
Key takeaways from the 2025 expert consensus document on cardiac computed tomography for prosthetic heart valve assessment
- 19 July 2025
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 19 (4) , 390-396
CT derived fractional flow reserve: Part 1 – Comprehensive review of methodologies
- 19 July 2025
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 19 (4) , 390-396
CT derived fractional flow reserve: Part 1 – Comprehensive review of methodologies
- Open Access
- 2 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4677
Efficacy and Safety of ACURATE neo2 in Valve-in-Valve TAVI: A Prospective Single-Center Study
Background/Objectives: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is a key approach for treating degenerated surgical bioprosthetic valves. The ACURATE neo2 valve, with its advanced sealing technology and optimized coronary access, represents a promising solution for the challenges of ViV TAVI. This study evaluates the procedural and 30-day and 1-year follow-up outcomes of the ACURATE neo2 valve in ViV TAVI. Methods: This single-center, single-operator prospective study included patients with symptomatic bioprosthetic valve dysfunction, classified in New York Heart Association (NYHA) class III or IV, who underwent ViV TAVI with ACURATE neo2 at our center between July 2022 and February 2024. Outcomes were assessed using VARC-3 criteria. Results: Fifty-five patients (51% females, median (IQR) age 76 (8) years) were included. The technical success rate was 98.2%. No patients experienced in-hospital mortality, stroke, MI, bleeding, vascular complications, renal failure, or new pacemaker implantation. Three patients (5.5%) underwent elective chimney stenting for coronary protection. The postprocedural mean aortic gradient was 6.7 ± 1 mmHg, with a mean aortic valve area (AVA) of 2.0 ± 0.1 cm2. Over a median follow-up period of 1.2 years, no deaths (0%) were observed, heart failure hospitalization rate was 3.6%, and NYHA class improved to ≤II in 100% of patients. Conclusions: ACURATE neo2 demonstrated excellent technical success, sustained hemodynamic performance, and significant clinical improvement in ViV TAVI. The absence of major adverse events reinforces its safety, efficacy, and durability as a treatment for degenerated surgical bioprostheses.
- 2 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4677
Open AccessEfficacy and Safety of ACURATE neo2 in Valve-in-Valve TAVI: A Prospective Single-Center Study
Background/Objectives: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is a key approach for treating degenerated surgical bioprosthetic valves. The ACURATE neo2 valve, with its advanced sealing technology and optimized coronary access, represents a promising solution for the challenges of ViV TAVI. This study evaluates the procedural and 30-day and 1-year follow-up outcomes of the ACURATE neo2 valve in ViV TAVI. Methods: This single-center, single-operator prospective study included patients with symptomatic bioprosthetic valve dysfunction, classified in New York Heart Association (NYHA) class III or IV, who underwent ViV TAVI with ACURATE neo2 at our center between July 2022 and February 2024. Outcomes were assessed using VARC-3 criteria. Results: Fifty-five patients (51% females, median (IQR) age 76 (8) years) were included. The technical success rate was 98.2%. No patients experienced in-hospital mortality, stroke, MI, bleeding, vascular complications, renal failure, or new pacemaker implantation. Three patients (5.5%) underwent elective chimney stenting for coronary protection. The postprocedural mean aortic gradient was 6.7 ± 1 mmHg, with a mean aortic valve area (AVA) of 2.0 ± 0.1 cm2. Over a median follow-up period of 1.2 years, no deaths (0%) were observed, heart failure hospitalization rate was 3.6%, and NYHA class improved to ≤II in 100% of patients. Conclusions: ACURATE neo2 demonstrated excellent technical success, sustained hemodynamic performance, and significant clinical improvement in ViV TAVI. The absence of major adverse events reinforces its safety, efficacy, and durability as a treatment for degenerated surgical bioprostheses.